IL276950B1 - Anti-cd73 antibodies and uses thereof - Google Patents
Anti-cd73 antibodies and uses thereofInfo
- Publication number
- IL276950B1 IL276950B1 IL276950A IL27695020A IL276950B1 IL 276950 B1 IL276950 B1 IL 276950B1 IL 276950 A IL276950 A IL 276950A IL 27695020 A IL27695020 A IL 27695020A IL 276950 B1 IL276950 B1 IL 276950B1
- Authority
- IL
- Israel
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- light chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL276950A IL276950A (en) | 2020-10-29 |
| IL276950B1 true IL276950B1 (en) | 2025-12-01 |
Family
ID=67846304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276950A IL276950B1 (en) | 2018-03-09 | 2020-08-26 | Anti-cd73 antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299550B2 (enExample) |
| EP (1) | EP3762030A4 (enExample) |
| JP (2) | JP7334177B2 (enExample) |
| KR (2) | KR102804816B1 (enExample) |
| CN (2) | CN118955714A (enExample) |
| AU (1) | AU2019231172B2 (enExample) |
| BR (1) | BR112020016049A2 (enExample) |
| CA (1) | CA3090008A1 (enExample) |
| IL (1) | IL276950B1 (enExample) |
| MX (1) | MX2020009366A (enExample) |
| SG (1) | SG11202007199XA (enExample) |
| WO (1) | WO2019173291A1 (enExample) |
| ZA (1) | ZA202004827B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| PE20251291A1 (es) | 2018-02-27 | 2025-05-14 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b |
| JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 |
| US11161850B2 (en) | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| WO2020072996A1 (en) | 2018-10-05 | 2020-04-09 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| MX2022003465A (es) * | 2019-09-23 | 2022-06-16 | Univ Pennsylvania | Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana. |
| CN114746438A (zh) | 2019-09-23 | 2022-07-12 | 宾夕法尼亚大学董事会 | 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂 |
| CN115003385A (zh) * | 2019-11-15 | 2022-09-02 | 建新公司 | 双互补位cd73抗体 |
| EP4061420A1 (en) * | 2019-11-20 | 2022-09-28 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| MX2022007513A (es) * | 2019-12-17 | 2022-07-05 | Phanes Therapeutics Inc | Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos. |
| CA3166536A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| WO2021202807A1 (en) * | 2020-03-31 | 2021-10-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| US12523662B2 (en) | 2020-04-02 | 2026-01-13 | Seattle Children's Hospital | Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia |
| US20230159655A1 (en) * | 2020-04-22 | 2023-05-25 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
| US20230151111A1 (en) * | 2020-04-22 | 2023-05-18 | Akeso Biopharma, Inc | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| WO2021222746A2 (en) * | 2020-04-30 | 2021-11-04 | Arch Oncology, Inc. | THERAPEUTIC SIRPα ANTIBODIES |
| CA3191745A1 (en) * | 2020-08-17 | 2022-02-24 | Akeso Biopharma, Inc. | Anti-cd73 antibody and use thereof |
| CA3196299A1 (en) * | 2020-10-23 | 2022-04-28 | Baiyong Li | Anti-cd73 antibody and use thereof |
| CN117126281A (zh) * | 2020-11-09 | 2023-11-28 | 江苏中新医药有限公司 | 抗cd73单克隆抗体及其在制备肿瘤药物中的应用 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| JP2024502005A (ja) | 2020-12-29 | 2024-01-17 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法 |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| EP4299589A4 (en) * | 2021-02-24 | 2025-06-11 | Novoprotein Scientififc Inc. | HUMAN ANTI-CD73 ANTIBODY AND ITS USE |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| IL310866A (en) * | 2021-08-19 | 2024-04-01 | Adicet Therapeutics Inc | Methods for the detection of membrane-bound glypican-3 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| US12187806B2 (en) * | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116063467B (zh) * | 2022-08-24 | 2025-10-14 | 浙江大学医学院附属第一医院 | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
| WO2024243189A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Antigen binding proteins targeting pd-1 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117567632B (zh) * | 2023-11-27 | 2025-10-24 | 福州迈新生物技术开发有限公司 | 抗cd73蛋白单克隆抗体及其制备方法和应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| WO2017100670A1 (en) * | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017152085A1 (en) * | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| US10654884B2 (en) | 2014-04-25 | 2020-05-19 | Boehringer Ingelheim International Gmbh | Purine derivatives as CD73 inhibitors for the treatment of cancer |
| KR102536786B1 (ko) | 2014-10-10 | 2023-05-26 | 이나뜨 파르마 에스.에이. | Ｃｄ７３ 차단 |
| MY191423A (en) * | 2014-11-10 | 2022-06-27 | Medimmune Ltd | Binding molecules specific for cd73 and uses thereof |
| EP3789403A1 (en) | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| EA035766B1 (ru) * | 2014-11-21 | 2020-08-07 | Бристол-Майерс Сквибб Компани | Антитело к cd73 и его применения |
| BR112017010094A2 (pt) | 2014-11-21 | 2018-02-06 | Bristol-Myers Squibb Company | anticorpos compreendendo regiões constantes de cadeias pesadas modificadas |
| WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
-
2019
- 2019-03-05 CN CN202411072731.7A patent/CN118955714A/zh active Pending
- 2019-03-05 CN CN201980018305.6A patent/CN111867628B/zh active Active
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
- 2019-03-05 KR KR1020207027633A patent/KR102804816B1/ko active Active
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 KR KR1020257013451A patent/KR20250065424A/ko active Pending
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en not_active Ceased
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
- 2020-08-26 IL IL276950A patent/IL276950B1/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP7636483B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| WO2017100670A1 (en) * | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017152085A1 (en) * | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111867628B (zh) | 2024-08-23 |
| CN111867628A (zh) | 2020-10-30 |
| BR112020016049A2 (pt) | 2020-12-08 |
| NZ766968A (en) | 2024-12-20 |
| WO2019173291A1 (en) | 2019-09-12 |
| CA3090008A1 (en) | 2019-09-12 |
| CN118955714A (zh) | 2024-11-15 |
| JP2023162257A (ja) | 2023-11-08 |
| KR20250065424A (ko) | 2025-05-12 |
| US20200399389A1 (en) | 2020-12-24 |
| JP7636483B2 (ja) | 2025-02-26 |
| US11299550B2 (en) | 2022-04-12 |
| SG11202007199XA (en) | 2020-09-29 |
| IL276950A (en) | 2020-10-29 |
| JP2021516057A (ja) | 2021-07-01 |
| AU2019231172A1 (en) | 2020-09-03 |
| KR102804816B1 (ko) | 2025-05-09 |
| KR20200128542A (ko) | 2020-11-13 |
| EP3762030A4 (en) | 2022-01-05 |
| JP7334177B2 (ja) | 2023-08-28 |
| ZA202004827B (en) | 2023-06-28 |
| AU2019231172B2 (en) | 2023-08-24 |
| MX2020009366A (es) | 2020-10-14 |
| EP3762030A1 (en) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11299550B2 (en) | Anti-CD73 antibodies and uses thereof | |
| US11401329B2 (en) | Anti-CD47 antibodies and uses thereof | |
| US12325745B2 (en) | Anti-DLL3 antibodies and uses thereof | |
| US11214615B2 (en) | Anti-TIM-3 antibodies and uses thereof | |
| CA3089653A1 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| US11390679B2 (en) | Anti-LAG-3 antibodies and uses thereof | |
| US11873335B2 (en) | Anti-folate receptor 1 antibodies and uses thereof | |
| HK40119299A (zh) | 抗cd73抗体及其用途 | |
| EA043284B1 (ru) | Антитела против cd73 и их применения | |
| HK40031477A (en) | Anti-cd73 antibodies and uses thereof |